• SIGN IN
  • GET HELP
  •  

    Home Study Details


    Program Type

    Home Study

    Credits

    2 Contact Hour(s)

    Release Date

    Friday, August 17, 2018

    Offline Date

    Monday, August 17, 2020

    ACPE Expiration Date

    Tuesday, August 17, 2021

    Target Audience

    Pharmacist, Nurse

    Cost

    $0.00

    • Overview

      Cystic fibrosis (CF) is a chronic progressive multi-organ disease prevalent worldwide varying by ethnic background. It is the most common life-shortening genetic disorder in North America, affecting 1 in 2000 Caucasian individuals. CF has autosomal recessive inheritance and is caused by a genetic mutation in a gene on chromosome 7 that encodes the cystic fibrosis transmembrane conductance regulator (CFTR) protein – a cyclic adenosine monophosphate (cAMP) regulated ion channel. Most patients diagnosed with CF have parents who do not have symptoms of CF but are heterozygote or carriers of the disease. As an autosomal recessive disease, patients need mutations in both CFTR alleles to develop CF and so it is equally common in both gender. 

      Handouts

      • Homestudy PDF :   18189H01.pdf

      Financial Support By

      Vertex Pharmaceuticals
    • Pharmacist

      Distinguish the requirements for patients who qualify for cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy.
      Describe the epidemiology and basic pathophysiology of cystic fibrosis (CF) & the organs affected.
      Employ best practices for patient counseling, as well as improving access and adherence to therapy.
      Analyze the improved disease progression in CF patients who have been initiated on CFTR modulation therapy.
      Identify the principles of precision medicine in CF patients that are currently impacting clinical practice.

      Nurse

      Identify the principles of precision medicine in CF patients that are currently impacting clinical practice.
      Employ best practices for patient counseling, as well as improving access and adherence to therapy.
      Analyze the improved disease progression in CF patients who have been initiated on CFTR modulation therapy.
      Describe the epidemiology and basic pathophysiology of cystic fibrosis (CF) & the organs affected.
      Distinguish the requirements for patients who qualify for cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy.
    • Activity Type

      Knowledge

      CE Broker

      20-630779

      Universal Activity Number

      Pharmacist 0798-0000-18-189-H01-P
      Nurse 0798-0000-18-189-H01-P

      ACPE PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      PharmCon is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

      In order to obtain a Statement of Credit, participants must score no less than a 70% on the activity's test and complete a program evaluation.


    HARDWARE REQUIREMENTS
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
     
     


    SOFTWARE REQUIREMENTS
    Microsoft Edge
    Internet Explorer 8.0 or higher
    Google Chrome
    Safari
    Firefox 3.0.3 or higher
    Adobe Acrobat Reader


    NETWORK REQUIREMENTS
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
     
     
     

    This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).